Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?

Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma in the US. For nearly 2 decades, standard front-line treatment has consisted of chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Numerous trials hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, James A., Shockley, Abigail, Herbst, Amanda, Hendrickson, Lindsey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894203/
https://www.ncbi.nlm.nih.gov/pubmed/36741209
http://dx.doi.org/10.6004/jadpro.2023.14.1.6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894203/
https://www.ncbi.nlm.nih.gov/pubmed/36741209
http://dx.doi.org/10.6004/jadpro.2023.14.1.6

Ejemplares similares